Back

Evaluation of Mid-position based treatment planning for stereotactic radioablation of ventricular tachycardia

31 March 2025 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Management of complex ventricular arrhythmias Radiotherapy EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Raphael Martins

Hospital Pontchaillou of Rennes, Rennes (France)

6 More presentations in this session

Presentation thumbnail
STAR SHAPe: validation of predictive features for redo catheter ablation using an explainable AI algorithm for stereotactic arrhythmia radioablation
Mr A. Mircea (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Radiosurgery for ventricular tachycardia (RAVENTA): Final results of a German multicenter multiplatform feasibility trial
Associate Professor O. Blanck (Kiel, DE)
Abstract Slides Video
Presentation thumbnail
Electrotomographic mapping: clinical translation for multipolar principal component referenced unipolar electrograms
Doctor N. Denham (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Survival, therapeutics and clinical prognosis after bidirectional ventricular tachycardia
Doctor R. Vazirani Ballesteros (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of stereotactic arrhythmia radioablation for ventricular arrhythmias using a novel multimodal fusion workflow for target delineation
Doctor M. Dezecot (Rennes, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Management of complex ventricular arrhythmias

The Event

Event poster

EHRA 2025

31 March 2025 13:30 CET
You may be interested in
thumbnail
Congress Presentation
3D target definition and initial results from the electroanatomic substrate-guided stereotactic ablative radiotherapy for refractory ventricular tachycardia (ELSTAR-VT)
thumbnail
Congress Presentation
Target volume definition and data transfer
thumbnail
Congress Presentation
Cardiac motion in patients with ventricular tachycardia: potential implications for the treatment of patients candidates to stereotactic arrhythmia radio-ablation (STAR)

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources